BiotechTube
Home/Pipeline/Recombinant Teriparatide

Recombinant Teriparatide

Osteoporosis

Pre-clinicalActive

Key Facts

Indication
Osteoporosis
Phase
Pre-clinical
Status
Active
Company
Paras Biopharmaceuticals Finland

About Paras Biopharmaceuticals Finland

Paras Biopharmaceuticals is a private, pre-revenue Finnish biotech focused on developing biosimilars and proprietary microbial expression technologies. The company operates a three-pronged business model encompassing a microbial biologics CDMO service, biosimilar technology development partnerships, and the sale of recombinant bioprocess enzymes. With a suite of proprietary platforms like Diabrid®, NobleCleav®, and Biomultifold®, Paras aims to enable cost-effective, high-yield production of complex therapeutic proteins and peptides. It is actively seeking partners to advance its pipeline of biosimilar candidates for osteoporosis, rheumatoid arthritis, and other conditions.

View full company profile

Therapeutic Areas

OsteoporosisRheumatoid ArthritisDiabetesOncologyOphthalmology

Other Osteoporosis Drugs

DrugCompanyPhase
Biosimilar to Prolia® (denosumab)TevaApproved/Under Review
TeriparatideEpygen BiotechNot Disclosed
AGA2118Angitia BiopharmaceuticalsPhase 2
Teriparatide (PTH 1-34) ProcessNumafermCommercial
Stoboclo®/Osenvelt®CelltrionMarketed
SHR-1222Jiangsu Hengrui MedicinePhase III
Biosimilar DenosumabRichter GedeonPhase III
Teriparatide InjectionAmphastar PharmaceuticalsMarketed
TST002 (Blosozumab)Transcenta TherapeuticsPhase 1